Related Experiment Videos
Idiopathic pulmonary haemosiderosis in Swedish children
Insights
Idiopathic pulmonary haemosiderosis in Swedish children is rare, affecting 0.24 per million annually. While iron and prednisone therapies showed some benefit, long-term outcomes improved significantly for those diagnosed later.
Area of Science:
- Pediatric Pulmonology
- Hematology
- Rare Diseases
Background:
- Idiopathic pulmonary haemosiderosis (IPH) is a rare condition causing lung bleeding and anemia.
- Understanding IPH incidence and clinical course in children is crucial for diagnosis and management.
Purpose of the Study:
- To determine the incidence and clinical characteristics of IPH in Swedish children.
- To evaluate the effectiveness of various therapeutic interventions for IPH.
- To assess long-term outcomes and survival rates in pediatric IPH patients.
Main Methods:
- Retrospective analysis of pediatric IPH cases in Sweden from 1950-1979.
- Review of complete medical records for children diagnosed between 1960-1979.
- Assessment of clinical symptoms, anemia type, pulmonary involvement, and treatment responses.
Main Results:
- The yearly risk of IPH onset was 0.24 per million children (1960-1979).
- Onset occurred at a mean age of 5.8 years, with severe sideropenic anemia present from diagnosis.
- Children diagnosed in the 1970s showed improved survival compared to those diagnosed in the 1960s, with one achieving complete remission.
Conclusions:
- IPH is a rare pediatric disease with a significant impact on lung and hematological health.
- While iron and prednisone therapies may offer temporary benefits, long-term prognosis appears to have improved over time.
- Further research is needed to elucidate the underlying causes and optimize treatment strategies for IPH.
Abstract:
During the 3 decades 1950-1979 onset of idiopathic pulmonary haemosiderosis occurred in 10 Swedish children. Complete records were available from the eight children with onset during 1960-1979, which indicates that the yearly risk of onset is 0.24 case per million children. The first symptoms started at the mean age of 5.8 years (range: 10 months-11 years). From the beginning all children had a severe microcytic, hypochromic, sideropenic anaemia. Pulmonary symptoms were present from the beginning in four children (but haemoptysis in only one) and developed in the remaining children after 1 1/2-2 1/2 years. Various therapeutical regimens were tried. Iron therapy seemed of temporary beneficial effect and most children seemed to benefit from prednisone therapy during disease bouts, although the effect of the therapy in the long run could not be determined. The four children with onsets during the 1960s died of their disease after 2-13 years. The four children with onset during the 1970s are still alive. One of them--a 20-year-old female, has for two years complete clinical remission and has normalized haematological, X-ray and pulmonary function data.